Yunkang provides solutions to member hospitals in medical institution alliances for building up and managing their diagnostic centers. The on-site diagnostic center is normally located at the lead hospital. Member hospitals within the same medical institution alliance may also use the diagnostic capacities of the center, as they will also deliver their test samples to the diagnostic center for testing. Therefore, our diagnostic testing services for medical institution alliances assist hospitals to better manage their diagnostic operation by centralizing and utilizing their resources to enhance the diagnostic capacities of the whole medical institution alliance.
Yunkang offers diagnostic outsourcing services to hospitals, other medical institutions and corporations at various levels. Facing the high volume of patient samples, under the premise of time- and cost-consuming testings performed by the hospitals, Yunkang provides a wide range of medical testing and clinical diagnostic services, including nucleic acid testing, genetic testing and diagnostic testing involving NGS technologies.
Yunkang is operating six independent clinical laboratories in a national scale, encompassing all major clinical laboratory technology platforms, including immunological detection, mass spectrometry, PCR, high-throughput sequencing, liquid chip, ultra-micro pathological morphology and digital pathology remote diagnosis. We have become a platform of medical operation service in China, covering major medical specialties of pathology, infectious diseases and genetic diseases with a growing menu of over 2,000 tests, which covered approximately 70% of major diagnostic testing categories in the medical operation service market in 2020, also over 50 million diagnostic tests performed in 2021.
Pathology tests primarily aim to discover and diagnose the nature of tumor. According to Frost & Sullivan, the number of new confirmed cancer cases in China increased from approximately 4.1 million in 2016 to approximately 4.6 million in 2020. Driven by factors including aging population and environmental factors, it is expected that there will be approximately 5.2 million confirmed cancer cases in 2025. Pathology tests are crucial for clinicians to accurately diagnose the pathological condition of each patient, so that they can provide timely, professional and efficient treatment plans.
With the growing awareness of infectious diseases, Yunkang has gradually built up our service offerings for over 20 categories of infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus and nucleic acid tests for respiratory pathogens (including COVID-19 virus), among others. In particular, since the occurrence of COVID-19 pandemic, COVID-19 testing has rapidly become a norm in daily life, as it is required for those in close contact with confirmed COVID-19 cases, those engaging international and cross-regional travel, and those having been exposed in high-risk environments. It is reported that Yunkang started to offer relevant professional services for COVID-19 testing (nucleic acid testing) as early as January 2020. Besides, the Guangzhou laboratory of Yunkang was included by the Guangdong Provincial Health Commission (廣東省衛生健康委) in the first batch of medical institutions with the COVID-19 nucleic acid testing capability.
Genetic disease diagnostic tests cover a very wide range of genetic reproduction tests and screening tests. According to Frost & Sullivan, the PRC government aims to increase the testing capacity of genetic reproduction tests to cover more than 50% of new birth populations in the PRC by 2022. In the field of genetic disease diagnostic testing, Yunkang can offer genetic screening tests at pre-pregnancy, pregnancy and new-born stages, aiming to help hospitals establish genetic pathology data for each patient so that they can design the most suitable treatment plan for the patient. It can even allow mothers to detect and prevent infectious disease and hereditary birth defects at pre-pregnancy and pregnancy stages, beneficial to prenatal and postnatal care.
In addition, Yunkang provides certain routine diagnostic tests for chronic kidney disease, blood disease, autoimmune disease, endocrine metabolism disease and other diseases.
Yunkang diagnostic testing services for non-medical institutions, including financial institutions and insurance companies, which mainly include personalized diagnostic testing, medical report consultation services and hospital referral services. Yunkang also provide health management services offline based on its customers' needs.